Toggle menu

TICH 2

Start date:
October 2013
End date:
February 2018
Co-ordinated by:
University of Nottingham
Main trial site:
http://tich-2.org

Tranexamic Acid for Hyperacute Primary IntraCerebral Haemorrhage

Aim

To assess whether tranexamic acid is safe and reduces death and dependency after hyperacute (within 8 hours of onset) spontaneous intracerebral haemorrhage.

Trial Design

A phase III prospective pragmatic double blind randomised placebo controlled trial

Chief Investigator

Dr Nikola Sprigg (Medical expert) Clinical Associate Professor, University of Nottingham

Principal Investigator

Professor Rustam Al-Shahi Salman, Professor of clinical neurology, University of Edinburgh & NHS Lothian

Local lead in ED

Dr Matt Reed is the local contact for recruitment of ED patients into the study.

Research Team

  • EMERGE Research team
  • Stroke Research Group

Eligibility criteria (summary)

Patients who present to the ED within 8 hours of acute spontaneous intracerebral haemorrhagic stroke.

Further information

For more information please refer to main trial website

Research Team

Dr Matt Reed

Consultant, NRS Career Research Fellow & Honorary Reader in Emergency Medicine

Bernadette Gallagher

Senior Research Nurse

More EMERGE Trials

This is a study looking at incidence and risk factors for poor ankle functional recovery, and the development and progression of post-traumatic ankle osteoarthritis after significant ankle ligament injury.

Read more

SALI Study

SALI study - Significant Ankle Ligament Injury

Global Anticoagulant Registry in the FIELD observing treatment and outcomes in patients with treated acute Venous Thromboembolic Events in the real world

Read more

Garfield-VTE

Global Anticoagulant Registry In the FIELD – Venous Thromboembolic Events

Evaluating the role of early CT Coronary Angiography on patients with suspected or confirmed Acute Coronary Syndrome.

Read more

RAPID-CTCA

Evaluating the role of early CT Coronary Angiography